Medivir’s U.S. commercialisation partner Meda presents positive Xerese™ data at ASHP

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that its U.S. commercialisation partner, Meda, has presented virolology data from the phase 3 programme on Xerese™/Xerclear®, Medivir’s unique cold sore treatment, at the 45th American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition, Anaheim, USA, 5-9 December 2010.   The poster[1] summarised the results of virology assessments from two phase 3 two-arm, randomised, multicenter, subject-initiated studies. These studies